Aarti Drugs Limited (NSE:AARTIDRUGS)
332.90
-15.60 (-4.48%)
Apr 4, 2025, 3:30 PM IST
Aarti Drugs Revenue
Aarti Drugs had revenue of 5.57B INR in the quarter ending December 31, 2024, a decrease of -8.14%. This brings the company's revenue in the last twelve months to 23.30B, down -12.10% year-over-year. In the fiscal year ending March 31, 2024, Aarti Drugs had annual revenue of 25.29B, down -6.90%.
Revenue (ttm)
23.30B
Revenue Growth
-12.10%
P/S Ratio
n/a
Revenue / Employee
21.90M
Employees
1,064
Market Cap
30.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 25.29B | -1.87B | -6.90% |
Mar 31, 2023 | 27.16B | 2.27B | 9.14% |
Mar 31, 2022 | 24.89B | 3.34B | 15.49% |
Mar 31, 2021 | 21.55B | 3.49B | 19.31% |
Mar 31, 2020 | 18.06B | 2.45B | 15.71% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Aarti Drugs News
- 7 weeks ago - Aarti Drugs receives US FDA clearance, removed from Import Alert 66-40 - Business Upturn
- 2 months ago - Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ... - GuruFocus
- 2 months ago - Aarti Drugs shares surge despite Q3 FY25 EBITDA margin falls to 11.1% - Business Upturn
- 2 months ago - Aarti Drugs Q3 FY25 results: Revenue down 8% to Rs 556.6 crore, Net Profit flat at Rs 37.09 crore - Business Upturn
- 3 months ago - Aarti Drugs shares surge 15% after receiving EIR from USFDA for API plant in Tarapur - Business Upturn
- 5 months ago - Aarti Drugs shares fall over 2% following poor Q2 FY25 results - Business Upturn
- 5 months ago - Aarti Drugs stock in focus as Q2 FY25 results show 6.3% revenue decline to ₹543.09 crore; profit falls 12.1% YoY to ₹40.99 crore - Business Upturn
- 5 months ago - Aarti Drugs Q2 FY25 Results: Revenue declines 6.3% YoY to Rs 543 crore, Profit falls 12% YoY - Business Upturn